Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

11.53 +0.26 (+2.31%)

Streaming Delayed Price Updated: 11:03 AM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 Next >

R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments

May 02, 2023

EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END

Via FinancialNewsMedia

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

November 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

November 07, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Third Quarter 2022 Financial Results

October 24, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

September 27, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

September 22, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference

September 07, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 10, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

August 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

July 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

June 08, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

June 01, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

May 09, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 03, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Report First Quarter 2022 Financial Results

April 26, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Pre-Clinical and Clinical Data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

April 25, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

April 14, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

February 22, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

February 11, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

AffaMed Therapeutics, licensee of DEXTENZA® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA® in China in Cataract Surgery Patients

January 18, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

January 04, 2022

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease

December 06, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences

November 15, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

November 09, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update

November 08, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®

November 05, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021

November 01, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results

October 29, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

October 28, 2021

From Ocular Therapeutix

Via Business Wire

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

October 22, 2021

From Ocular Therapeutix, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.